Variable inhibitory effects on the formation of dinitrosyl iron complexes by deferoxamine and salicylaldehyde isonicotinoyl hydrazone in K562 cells

Hemoglobin

Volumn 32, Issue 1-2, 2008, Pages 157-163

  Meczynska, Sylwia ^a   Lewandowska, Hanna ^a   Sochanowicz, Barbara ^a   Sadlo, Jaroslaw ^a   Kruszewski, Marcin ^a  

^a INSTITUTE OF NUCLEAR CHEMISTRY AND TECHNOLOGY   (Poland)

Author keywords

Deferoxamine mesylate (DFO); Diethylamine nitric oxide (DEANO); Electron paramagnetic resonance (EPR); Iron (Fe); K562 cells; Nitric oxide (NO); Salicylaldehyde isonicotinoyl hydrazone (SIH)

Indexed keywords

DEFEROXAMINE MESYLATE; IRON CHELATING AGENT; IRON COMPLEX; SALICYLALDEHYDE ISONICOTINOYL HYDRAZONE; UNCLASSIFIED DRUG;

CHELATION THERAPY; CONFERENCE PAPER; DRUG INHIBITION; DRUG SOLUBILITY; DRUG STRUCTURE; ELECTRON SPIN RESONANCE; ERYTHROID CELL; HUMAN; HUMAN CELL; INTRACELLULAR SPACE; IRON CHELATION; LIPID SOLUBILITY; MEMBRANE PERMEABILITY; MOLECULAR WEIGHT; PINOCYTOSIS;

ALDEHYDES; DEFEROXAMINE; ELECTRON SPIN RESONANCE SPECTROSCOPY; HUMANS; HYDRAZONES; IRON; IRON CHELATING AGENTS; K562 CELLS; NITRIC OXIDE; NITROGEN OXIDES;

EID: 39349117541     PISSN: 03630269     EISSN: 1532432X     Source Type: Journal    
DOI: 10.1080/03630260701699821     Document Type: Conference Paper

References (22)

1. Drapier JC, Pellat C, Henry Y. Generation of EPR-detectable nitrosyl-iron complexes in tumor target cells cocultured with activated macrophages. J Biol Chem 1991; 266(16):10162-10167.
2. Bastian NR, Yim CY, Hibbs JB Jr, Samlowski WE. Induction of iron-derived EPR signals in murine cancers by nitric oxide. Evidence for multiple intracellular targets. J Biol Chem 1994; 269(7):5127-5131.
3. Pieper GM, Halligan NL, Hilton G, Konorev EA, Felix CC, Roza AM, Adams MB, Griffith OW. Nonheme iron protein: a potential target of nitric oxide in acute cardiac allograft rejection. Proc Natl Acad Sci USA 2003; 100(6):3125-3130.
4. Pillay CS, Elliott E, Dennison C. Endolysosomal proteolysis and its regulation. Biochem J 2002; 363(Pt 3):417-429.
5. Vanin A, Kleschyov A. EPR detection and biological implications of nitrosyl iron complexes. In: Lukiewicz S, Zweier JL, Eds. Nitric Oxide in Transplant Rejection and Anti-Tumor Defence. Boston: Kluwer Academic Publishing, 1999; 49-82.
6. Ueno T, Yoshimura T. The physiological activity and in vivo distribution of dinitrosyl dithiolato iron complex. Jpn J Pharmacol 2000; 82(2):95-101.
7. Vanin AF. Dinitrosyl iron complexes and S-nitrosothiols are two possible forms for stabilization and transport of nitric oxide in biological systems. Biochemistry (Mosc) 1998; 63(7):782-793.
8. Keese MA, Bose M, Mulsch A, Schirmer RH, Becker K. Dinitrosyl-dithiol- iron complexes, nitric oxide (NO) carriers in vivo, as potent inhibitors of human glutathione reductase and glutathione-S-transferase. Biochem Pharmacol 1997; 54(12):1307-1313.
9. Henry Y, Ducrocq C, Drapier JC, Servent D, Pellat C, Guissani A. Nitric oxide, a biological effector. Electron paramagnetic resonance detection of nitrosyl-iron-protein complexes in whole cells. Eur Biophys J 1991; 20(1):1-15.
10. Kruszewski M. Labile iron pool: the main determinant of cellular response to oxidative stress. Mutat Res 2003; 531(1-2):81-92.
11. Porter JB, Gyparaki M, Burke LC, Huehns ER, Sarpong P, Saez V, Hider RC. Iron mobilization from hepatocyte monolayer cultures by chelators: the importance of membrane permeability and the iron-binding constant. Blood 1988; 72(5):1497-1503.
12. Laub R, Schneider YJ, Octave JN, Trouet A, Crichton RR. Cellular pharmacology of deferrioxamine B and derivatives in cultured rat hepatocytes in relation to iron mobilization. Biochem Pharmacol 1985; 34(8):1175-1183.
13. Cable H, Lloyd JB. Cellular uptake and release of two contrasting iron chelators. J Pharm Pharmacol 1999; 51(2):131-134.
14. Richardson DR, Tran EH, Ponka P. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Blood 1995; 86(11):4295-4306.
15. Hershko CM, Link GM, Konijn AM, Cabantchik ZI. Iron chelation therapy. Curr Hematol Rep 2005; 4(2):110-116.
16. Sterba M, Popelova O, Simunek T, Mazurova Y, Potacova A, Adamcova M, Guncova I, Kaiserova H, Palicka V, Ponka P, Gersl V. Iron chelation-afforded cardioprotection against chronic anthracycline cardiotoxicity: A study of salicylaldehyde isonicotinoyl hydrazone (SIH). Toxicology 2007; 235(3):150-166.
17. Sterba M, Popelova O, Simunek T, Mazurova Y, Potacova A, Adamcova M, Kaiserova H, Ponka P, Gersl V. Cardioprotective effects of a novel iron chelator, pyridoxal 2-chlorobenzoyl hydrazone, in the rabbit model of daunorubicin-induced cardiotoxicity 4. J Pharmacol Exp Ther 2006; 319(3):1336-1347.
18. Zanninelli G, Glickstein H, Breuer W, Milgram P, Brissot P, Hider RC, Konijn AM, Libman J, Shanzer A, Cabantchik ZI. Chelation and mobilization of cellular iron by different classes of chelators. Mol Pharmacol 1997; 51(5):842-852.
19. Kennedy MC, Antholine WE, Beinert H. An EPR investigation of the products of the reaction of cytosolic and mitochondrial aconitases with nitric oxide. J Biol Chem 1997; 272(33):20340-20347.
20. Kwok JC, Richardson DR. Anthracyclines induce accumulation of iron in ferritin in myocardial and neoplastic cells: inhibition of the ferritin iron mobilization pathway. Mol Pharmacol 2003; 63(4):849-861.
21. Kwok JC, Richardson DR. Examination of the mechanism(s) involved in doxorubicin-mediated iron accumulation in ferritin: studies using metabolic inhibitors, protein synthesis inhibitors, and lysosomotropic agents. Mol Pharmacol 2004; 65(1):181-195.
22. Konijn AM, Glickstein H, Vaisman B, Meyron-Holtz EG, Slotki IN, Cabantchik ZI. The cellular labile iron pool and intracellular ferritin in K562 cells. Blood 1999; 94(6):2128-2134.